Skip to main content

Advertisement

SpringerLink
Log in

Issues and controversies in the treatment of HER2 positive metastatic breast cancer

  • Review
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Targeted therapies against the human epidermal growth factor receptor HER2, have led to revolutionary strides in breast cancer research and treatment. Clinical therapeutic decisions in the treatment of patients with HER2 positive metastatic breast cancer are based on appropriate patient selection, the clinical situation, and data related to the available therapeutic agents trastuzumab and lapatinib. Trastuzumab was the first agent tested and approved in 1996 as single agent for patients with chemotherapy-refractory disease, and in combination with paclitaxel as first-line treatment. This intravenous humanized monoclonal antibody is directed against the extracellular domain of the HER2 protein. Lapatinib, an oral small molecule tyrosine kinase inhibitor has more recently become available (in 2007), approved for used in combination with capecitabine for patients with HER2 positive metastatic disease that has progressed on trastuzumab. Important questions and controversies still remain and are reviewed, including patient selection for anti-HER2 treatment of metastatic disease based on HER2 testing, dose scheduling of trastuzumab, duration of therapy, tolerability, role of lapatinib and clinical significance of trastuzumab resistance and efficacy. Ongoing trials designed to maximize the therapeutic ratio of these agents, are also discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Wolff AC, Hammond M, Schwartz JN et al (2007) American society of clinical oncology/College of American pathologists guideline recommendations for human epidermal growth factor receptor 2 Testing in breast cancer. J Clin Oncol 25(1):118–145

    Article  PubMed  CAS  Google Scholar 

  2. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M et al (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2–overexpressing metastatic breast cancer. J Clin Oncol 20(3):719–726

    Article  PubMed  CAS  Google Scholar 

  3. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G et al (1999) Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17(9):2639–2648

    PubMed  CAS  Google Scholar 

  4. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344(11):783–792

    Article  PubMed  CAS  Google Scholar 

  5. ®Herceptin: Trastuzumab: prescribing information. San Francisco (CA): Genentech Inc 2005 Feb

  6. Harris K, Washington CB, Lieberman J-F et al (2002) A population pharmacokinetic (PK) model for trastuzumab (Herceptin) and implications for clinical dosing. In: Proc Am Soc Clin Oncol: 2002: 123

  7. Baselga J, Carbonell X, Castaneda-Soto NJ, Clemens M, Green M, Harvey V, Morales S, Barton C, Ghahramani P (2005) Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol 23(10):2162–2171

    Article  PubMed  CAS  Google Scholar 

  8. Cortes J, Climent M, Lluch A et al (2004) Updated results of a phase II study (M77035) of Myocet combined with weekly Herceptin and paclitaxel in patients (pts) with HER2-positive locally advanced or metastatic breast cancer (LABC/MBC). Breast Cancer Res Treat 88(Suppl 1, abstract 3041)

  9. Marcom PK, Isaacs C, Harris L et al (2005) A phase II trial of letrozole and trastuzumab for ER and/or PgR and HER2 positive metastatic breast cancer: Final results. J Clin Oncol 23(16S):596a

    Google Scholar 

  10. Mackey JR, Kaufman B, Clemens M et al (2006) Trastuzumab prolongs progression-free survival in hormone-dependent and HER2-positive metastatic breast cancer. Breast Cancer Res Treat 100(suppl 1, abstract 3)

  11. Burris H 3rd, Yardley D, Jones S, Houston G, Broome C, Thompson D, Greco FA, White M, Hainsworth J (2004) Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer. J Clin Oncol 22(9):1621–1629

    Article  PubMed  CAS  Google Scholar 

  12. Pegram MD, Pienkowski T, Northfelt DW, Eiermann W, Patel R, Fumoleau P, Quan E, Crown J, Toppmeyer D, Smylie M et al (2004) Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer. J Natl Cancer Inst 96(10):759–769

    Article  PubMed  CAS  Google Scholar 

  13. Robert N, Leyland-Jones B, Asmar L, Belt R, Ilegbodu D, Loesch D, Raju R, Valentine E, Sayre R, Cobleigh M et al (2006) Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 24(18):2786–2792

    Article  PubMed  CAS  Google Scholar 

  14. Forbes JF, Kennedy J, Pienkowski T et al (2006) BCIRG 007: randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin first line in HER2 positive metastatic breast cancer (MBC). J Clin Oncol 24(suppl (18S), abstract 516)

  15. Network NCC (2007) NCCN Clinical Practice Guidelines in Oncology. v12007

  16. Konecny GE, Pegram MD, Venkatesan N, Finn R, Yang G, Rahmeh M, Untch M, Rusnak DW, Spehar G, Mullin RJ et al (2006) Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells.1630–1639, Feb 1631

  17. Burris HA 3rd,Hurwitz HI, Dees EC et al (2005) Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol 23(23):5305–5313

    Article  PubMed  CAS  Google Scholar 

  18. Blackwell KL, Burstein H, Pegram M et al (2005) Determining relevant biomarkers from tissue and serum that may predict response to single agent lapatinib in trastuzumab refractory metastatic breast cancer. J Clin Oncol 23(suppl (16S), abstract 3004)

  19. Gomez HL, Chavez MA, Doval DC et al (2005) A phase II, randomized trial using the small molecule tyrosine kinase inhibitor lapatinib as a first-line treatment in patients with FISH positive advanced or metastatic breast cancer. J Clin Oncol 23(suppl (16S), abstract 3046)

  20. Geyer CE, Forster J, Lindquist D et al (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355(26):2733–2743

    Article  PubMed  CAS  Google Scholar 

  21. Storniolo A, Burris H, Pegram M et al (2005) A phase I, open-label study of lapatinib (GW572016) plus trastuzumab; a clinically active regimen. J Clin Oncol 23(suppl (16S), abstract559)

  22. Clayton AJ, Danson S, Jolly S, Ryder WD, Burt PA, Stewart AL, Wilkinson PM, Welch RS, Magee B, Wilson G et al (2004) Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer.639–643, Aug 2016

  23. Burstein HJ, Lieberman G, Slamon DJ, Winer EP, Klein P (2005) Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy.1772–1777, Nov

  24. Lin NU, Carey LA, Liu MC et al (2006) Phase II trial of lapatinib for brain metastases in patients with HER2+ breast cancer. J Clin Oncol 24(suppl (18S), abstract 503)

  25. Ewer MS, Vooletich MT, Durand JB, Woods ML, Davis JR, Valero V, Lenihan DJ (2005) Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment.7820–7826, Nov 7821

  26. Perez EA, Bryant J, Rappold E, Preston A, Koehler M, Ewer M (2006) Cardiac safety experience in 3558 patients treated with lapatinib. European Society of Medical Oncology ESMO Presentation

  27. Bramwell VHC, Doig GS, Tuck AB et al (2006) Serial measurement of serum extracellular domain of HER2 (ECD/HER2) has prognostic value in metastatic breast cancer. Breast Cancer Res Treat 100(suppl 1, abstract 1005)

  28. Kashiwaba M, Inaba T, Wakabayashi G (2006) Serum HER2/nue extra-cellualar domain level predicts clinical response in the patients treated with sequential trastuzumab monotherapy and combination with chemotherapy. Breast Cancer Res Treat 100, suppl 1:abstract 1008

  29. Dinocca S, Blot E, Laberge-Le-Couteulx S et al (2006) Serum level of HER2 extra cellular domain (ECD) is a significant prognostic factor for survival in metastatic breast cancer without HER2 overexpression on primary tumor. Breast Cancer Res Treat 100(suppl 1, abstract 1035)

  30. Tripathy D, Mukhopadhyay P, Sikder K et al (2006) Genomic and proteomic alterations in acquired trastuzumab resistance. Breast Cancer Res Treat 100(suppl 1, abstract 309)

  31. Price-Schiavi SA, Jepson S, Li P, Arango M, Rudland PS, Yee L, Carraway KL (2002) Rat Muc4 (sialomucin complex) reduces binding of anti-ErbB2 antibodies to tumor cell surfaces, a potential mechanism for herceptin resistance.783–791, Jun 2020

  32. Nahta R, Yuan LX, Zhang B, Kobayashi R, Esteva FJ (2005) Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res 65(23):11118–11128

    Article  PubMed  CAS  Google Scholar 

  33. Lu Y, Zi X, Pollak M (2004) Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells.334–341, Jan 2020

  34. Nahta R, Yuan LX, Zhang B, Kobayashi R, Esteva FJ: Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells.11118–11128, 12005 Dec 11111

  35. Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, Klos KS, Li P, Monia BP, Nguyen NT et al (2004) PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.[see comment].117–127, Aug

  36. Fuino L, Bali P, Wittmann S, Donapaty S, Guo F, Yamaguchi H, Wang HG, Atadja P, Bhalla K (2003) Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B.971–984, Oct

  37. Widdison WC, Wilhelm SD, Cavanagh EE, Whiteman KR, Leece BA, Kovtun Y, Goldmacher VS, Xie H, Steeves RM, Lutz RJ et al (2006) Semisynthetic maytansine analogues for the targeted treatment of cancer. J Med Chem 49(14):4392–4408

    Article  PubMed  CAS  Google Scholar 

  38. Xia W, Bacus S, Hegde P, Husain I, Strum J, Liu L, Paulazzo G, Lyass L, Trusk P, Hill J et al (2006) A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer.7795–7800, May 7716

Download references

Author information

Authors and Affiliations

  1. Mayo Clinic Jacksonville, 4500 San Pablo Rd, Jacksonville, FL, 32224, USA

    Surabhi Amar, Alvaro Moreno-Aspitia & Edith A. Perez

Authors
  1. Surabhi Amar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alvaro Moreno-Aspitia
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Edith A. Perez
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Edith A. Perez.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Amar, S., Moreno-Aspitia, A. & Perez, E.A. Issues and controversies in the treatment of HER2 positive metastatic breast cancer. Breast Cancer Res Treat 109, 1–7 (2008). https://doi.org/10.1007/s10549-007-9636-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-007-9636-2

Keywords

Search

Navigation